Category Archives: Pharma

Is Novel Drug Delivery System responsible for the Enhanced Drug Delivery?


Novel Drug Delivery System comprising the methods namely

  • Transdermal Drug Delivery system
  • Carrier Based Drug delivery system

Both the methods have been a revolution in the field of drug delivery and distribution. The aspects like bio availability of the drug to the body and specificity of the target in body has been optimized by the improvements and discoveries made in the field of novel drug delivery system.

Targeted drug delivery system has been the major motto of the NDDS from the very start of the subject inclusion as an result many wonders are been discovered year by year which are leading to the optimized and enhanced mechanism of drug distribution and delivery with specificity in the target

Transdermal Drug Delivery System

|| Sonophoresies

  • Mucoadhesive Delivery System
  • Supramolecular Delivery System
  • Variable Release Delivery System

|| Osmatic Pump

|| Microencapsulation

Transdermal Drug delivery system has been the major aspect to be discussed that had given the release from administration of pain killers which is leading to drug abuse. The transdermal drug delivery patches has been the major development which later have been used not only as pain killers or analgesics but also many other targeted drug administrations.

Pros: No dose dumping, No internal administration, no drug drug interactions

Cons: Dermal infections.

Carrier Based Drug Delivery System

|| Liposomes

|| Nanoparticles

|| Microspheres

|| Resealed Erythrocytes

|| Monoclonal Antibodies


7Pharmacy is the science and strategy of planning and dispensing drugs. It may be a health profession that joins the health sciences with chemical sciences and points to ensure the safe and effective utilization of pharmaceutical drugs. The scope of pharmacy practice incorporates more conventional parts such as compounding and dispensing medications, and it too incorporates more advanced administrations related to health care, including clinical administrations, reviewing medicines for security and adequacy, and providing drug data.

ME Conferences take privilege to welcomes you to attend 2nd Middle East Pharmacy and Pharmaceutical Conference scheduled to be held during December 09-10, 2019 at Dubai, UAE with the theme “Innovative Researches and Developments in Pharmaceutical Sciences”.

Pharma Conference 2019 forecasts existence of keynote speeches, session speeches, delegates, young researchers and students around the world. This conference perhaps a giant event that creates an ideal platform to share expertise addressing current advancements involved in Pharmaceutical Sciences and Pharmaceutical Technology. It will be a wonderful opportunity for all the delegates as it provides an international networking opportunity to collaborate with the world class pharma associations and societies.

Conference Sessions:

  • Pharmaceutical Sciences
  • Pharmacy
  • Novel Drug Delivery Systems
  • Pharmacology and Toxicology
  • Biologic and Biosimilar
  • Pharmaceutical Technology
  • Drug Discovery and Design
  • Bioavailability and Bioequivalence
  • Clinical Research and Clinical Trials
  • Pharmacognosy and Phytochemistry
  • Pharmaceutical Care
  • Drug Formulation & Analytical Techniques
  • Recent trends in Pharma and Technology
  • Clinical Pharmacy
  • Pharma Pricing and Market Research
  • Pharmacovigilance & Regulatory Affairs

Book Mark your Dates for 2nd Middle East Pharmacy and Pharmaceutical Conference in Dubai, UAE for more recent updates in Pharmaceutical Sciences  and Pharmaceutical Technology.

Acupuncture on the rise in Middle East



Holistic medicine treatments are on the rise in the Middle East region and that includes the use of acupuncture. More and more emirati peoples are looking for approaches that treat the whole person instead of just physical symptoms. According to a National Survey that looked at a five-year period, acupuncture is one of the treatment that is on the rise.

What is acupuncture?

It’s a form of holistic treatment rooted in ancient traditional medicine that involves the insertion of needles at specific points on the body, also called acupoints. The practice helps improve the flow of Qi or Chi life force energy and treat a variety of ailments, depending on which points are targeted.

Researchers found that by the study’s completion over 10 million Middle-East citizens used or had tried acupuncture. That is a significant increase from the beginning of the study period, which found only 6.19 million acupuncture patients in the Middle-East.

Data from this survey shows an growth in the uses of acupuncture from approximately 4% to 6% of people in Dubai over five years, and indicates a trend for the mainstreaming of acupuncture in the Dubai.

Survey investigators included health experts from the various universities in Middle-East.

What patients reported2

According to the survey the patients used acupuncture as a complementary and alternative approach to conventional treatment for a specific health condition, but also used it as a preventative means to promote general health. The investigators predicted a continuation of the upward trend.

The increase in the use of acupuncture as a treatment method is mostly due to the fact that more persons are realizing that it is an effective and low-risk method of treating or controlling chronic conditions. Insurance coverage for acupuncture services and increased awareness of acupuncture may contribute to the popularity and growth of acupuncture use in the Dubai the investigators noted.

How acupuncture helps

Acupuncture helps treat a variety of acute and chronic conditions. It also contributes to general health and wellness. The benefits of acupuncture include:

  • Maintains general wellness
  • Strengthens constitution
  • Increases vitality
  • Promotes energy flow within the body

Acupuncture may be used either as a preventative therapy or to effectively treat a wide range of health conditions, including: digestive problems, insomnia and sleep disorders, migraines and other types of headaches, back pain, osteoarthritis, circulatory problems and sciatica, among others. It also helps with issues like mood swings, depression, anxiety and even post-traumatic stress disorder (PTSD).

Acupuncture can be used alongside conventional medicine in the treatment of both acute and chronic diseases.

Interested organization who deals with Acupuncture and others related traditional medicine are welcome to join their hands as an exhibitor, speaker or in workshop participation in our upcoming conference Pharma Traditional Medicine 2019 during June 20-21 in Dubai.

Drug Bioavailability

Drug Bioavailability can be known as the active amount of drug reaches the systemic circulation to the site of action. The Bioavailability of the drug depends on the form of dosage and also its design and the manufacturing. The differences in the bioavailability between the drugs will have the clinical significance so, knowing the equivalence of the formulations is needed.

If the formulations contain the same active compound in the same quantity and also reaches the official standards they are chemically equivalent, however, inactive compounds in the formulation may differ. When the plasma concentrations of two different drugs given to the same patient in same dosage regimen are the same then it’s considered as bioequivalence. If they show the same therapeutic and adverse effects then they are therapeutically equivalent. The bioequivalent products are ought to be therapeutically equivalent. Therapeutic non-equivalence is also observed during the long term treatment of the patient who is stabilized on one formulation is given with the non-equivalent substitute.

Causes of low bioavailability

  • Metabolisation of drugs before reaching adequate plasma concentrations. This usually occurs in the oral dosage forms that are poorly water-soluble and slowly absorbed.
  • Insufficient time of absorption in the GI tract.
  • Age, sex, physical activity, genetic phenotype, stress, disorders
  • Chemical reactions that reduce the absorption. The reactions include complex formation, hydrolysis by gastric acid or digestive enzymes, adsorption to other drugs, metabolism by luminal microflora.

Assessing bioavailability


The assessment of the bioavailability is done by determining the area under the plasma concentration-time curve. AUC is the most reliable measure of the drug bioavailability. If plasma concentration curves are superimposable then drug products may be considered as bioequivalent in extent and rate of absorption. The drugs that are excreted primarily unchanged in urine, bioavailability will be determined by measuring the total amount of drug excreted after every single dose.


Pharma Middle East 2019 is the most suitable platform to explore ones’ scientific knowledge by sharing through their presentations and to build a robust network with the eminent people, key decision makers from all-around the academic institutions, Healthcare Institutes, Pharmaceutical, Biotech organizations of the world. The conference aims to build a strong belief that all other health and medical sciences can provide the healthy circumstances by the inter-bonding with the Pharmaceutical studies and sciences and hence the theme Explore the Alliance of Pharmaceutical & Health Sciences.1

Conference Sessions

Pharmacy and Pharmaceutical Sciences

Anatomy & Pathophysiology

Bioinformatics and Bio-materials

Pharmacognosy & Botony

Nanotechnology in Pharmacy

Medicinal & Biological Chemistry

Pharmacological Studies

Insights of Cancer Pharmacology

Clinical Pharmacy & Pharmaceutical Care

Pharmaceutical Biotechnology and Microbiology

Pharmaceutical Ethics & Regulatory Affairs

Future of Pharmacy & Pharmacists

Traditional Medicine & Phytochemistry

Pharmaceutical Industry & Business Management

#Pharmaceuticalconferences #pharmameetings #TurkishPharma #TurkeyTourism #Istanbulconferences #Pharmacyconferences #workshops #symposium #postercompetition

Bioinspired Nanoscale Tranquilize Conveyance Technique

Analysts have built up a novel method to convey medications and treatments into cells at the nanoscale without causing harmful impacts that have frustrated other such endeavors. The work could some time or another lead to progressively viable treatments and diagnostics for disease and different ailments.

Pharmacology Blog1

The work could some time or another lead to progressively compelling treatments and diagnostics for malignant growth and different ailments.

The examination group grew organically roused materials at the nanoscale that could viably convey show restorative qualities into tumor cells. Analysts have been attempting to create nanomaterials that can adequately convey remedial qualities specifically into the phones for the treatment of illnesses, for example, malignant growth. The key issues for quality conveyance utilizing nanomaterials are their low conveyance effectiveness of drug and potential lethality.

Pharmacology Blog 2

 To create nanotechnology for therapeutic purposes, the main interesting point is harmfulness.

The flower like molecule created is around 150 nanometers in size, or around one thousand times littler than the width of a bit of paper. It is made of sheets of peptoids, which are like normal peptides that make up proteins. The peptoids make for a decent medication conveyance molecule since they’re genuinely simple to blend and, in light of the fact that they’re like characteristic organic materials, function admirably in natural frameworks.

 The scientists included fluorescent tests in their peptoid nanoflowers, so they could follow them as they advanced through cells, and they included the component fluorine, which helped the nanoflowers all the more effectively escape from precarious cell traps that regularly block medicate conveyance

Pharmacology Blog 3

The flower like particles stacked with remedial qualities could advance easily out of the anticipated cell trap, enter the core of the cell, and discharge their medication there. The nanoflowers effectively and quickly got away from (the cell trap) and showed insignificant cytotoxicity.

 After their underlying testing with model medication particles, the specialists plan to direct further examinations utilizing genuine drugs. This clears another path for us to create nanocargoes that can proficiently convey medicate atoms into the cell and offers new open doors for focused quality treatments.


Among the rundown of more than 300 FDA and EMA affirmed biopharmaceutical items, around half are solidify dried – demonstrating that solidify drying is the favored method for balancing out biopharmaceutical sedate items that are unsteady in fluid arrangement, in spite of the mind-boggling expense and long preparing time connected to this assembling strategy.

Freeze drying is a low-temperature drying process, standards of warmth and mass exchange are utilized to change over fluid arrangements of (warm) labile materials into solids with adequate security for conveyance and storage. Many biopharmaceuticals have restricted solidness in watery arrangement and are liable to various corruption pathways interceded by water, which may result in a lower strength or even in danger of the medication atom. A pharmaceutical Freeze drying process comprises of three successive advances.

  • During solidifying the greater part of the water takes shape to ice, accordingly focusing the solutes between the ice precious stones. A portion of the solutes take shape amid solidifying, while those that don’t are changed into an inflexible glass
  • The ice gems are expelled under vacuum by sublimation (essential drying). Warmth is provided to the solidified item for sublimation, yet the item temperature is kept underneath the fall temperature to keep away from auxiliary item crumple, subsequently guaranteeing a strong and inflexible dried cake after freeze drying
  • A optional drying step where the greater part of the unfrozen water (i.e., water broke up in the indistinct stage) is expelled by dispersion and desorption.

The most imperative basic quality characteristics assessed after stop drying on haphazardly chosen tests utilizing disconnected logical strategies are: (I) the API state (e.g. protein compliance) and security; (ii) the lingering dampness content; (iii) the freeze dried item cake appearance; (iv) the reconstitution time.

For over 80 years, pharmaceutical stop drying has been performed utilizing an unaltered bunch shrewd methodology, despite the fact that the taking care of gear previously (filling) and in the wake of (topping and bundling) solidify drying is ceaselessly worked essentially. A common pharmaceutical Freeze dryer comprises of a vacuum drying chamber in which the pharmaceutical unit dosages (vials) are put on temperature controlled racks. Freeze drying performed by means of this customary cluster shrewd methodology has a few detriments:

The solidifying step is uncontrolled, which has the huge effect on the successive drying steps. Solidifying at first includes the cooling of every single fluid arrangement (vials) in the stop dryer until ice nucleation happens, which is by and large underneath 0°C (i.e., supercooling). Ice nucleation is a stochastic occasion, henceforth actuating vial-to-vial variety dependent on the level of supercooling: a higher level of supercooling yields a high number of little ice precious stones while at a lower level of supercooling, a lower number of substantial ice gems is shaped. As an outcome, the measure of the ice gems contrasts from vial to vial, which influences the individual vial sublimation rate amid essential drying.

Uneven warmth move in the Freeze drying chamber results in various vitality exchanges to vials at various areas on the stop dryer racks. For example, vials arranged at the edge of the racks are presented to more brilliant warmth from the hotter environment (i.e., entryway and dividers of the freeze dryer) contrasted with the vials amidst the racks. This vial-to-vial inconstancy in warmth move results in noteworthy vial-to-vial contrast towards item temperature (risk for fall) and drying rate.

Current Trends in Clinical Trials

Clinical Trials are the studies which covers high quality manuscripts both relevant and applicable to the broad field of experiments or observations done in clinical research. These studies renders novel, clear connection with clinical practitioners, medical/ health practitioners, students, professionals, researchers, professional bodies and institutions.

Focus and Scope
Currently Clinical Trials objective is to maintain and develop science and related research at an international level. It is important to bring into light of outstanding research and development results to the world instantaneously in latest advancements towards clinical trials to achieve objective of the clinical trials.

 Highlighted Topics

  • Adverse Event Monitoring
  • Biomarkers in Clinical Trials
  • Biostatistics
  • Cancer Clinical Trials
  • Clinical Case Studies
  • Clinical Practice Guidelines
  • Clinical Progress for Specific Diseases or Therapeutic Areas
  • Clinical Research & Bioethics
  • Clinical Study Design and Methodology
  • Clinical Trial Data Management and Statistics
  • Clinical Trial Methodology
  • Clinical Trials
  • Clinical Trials Data Management & Software
  • Clinical Trials Europe
  • Clinical Trials Japan
  • Clinical Trials USFDA
  • Contemporary Clinical Trials
  • Data Auditing Methodologies
  • Diabetic Trials
  • Drug Clinical Trials
  • Drug Safety Issues
  • Findings in Phase -I to -IV clinical studies
  • Healthcare Outcomes and Pharmacoeconomics
  • HIV Clinical Trials
  • Overviews of the Clinical Progress of New Drugs or Drug Classes
  • Pharmacy Marketing
  • Patient Stratification and Individualized Therapies
  • Pilot Studies
  • Preclinical Trials
  • Protocol
  • Psychiatric Studies
  • Quality Assurance & Data Auditing Methodologies
  • Randomized Controlled Trials
  • Regulatory Aspects of Clinical Trials
  • Regulatory Issues
  • Rehabilitation Protocols

 Seven trends that should be familiar to all in clinical development:

  1. Increasingly complex trials: More and more interest is building in iteratively modifying parameters of a trial protocol based on real-time outcomes
  2. Precision medicine: Precision medicine is on the rise as the technology increases to administer therapeutics to patients in highly individualized ways.
  3. Virtual trials: Virtual clinical trials represent a new method of collecting safety and efficacy data from clinical trial participants through the use of mobile health (mHealth) technology without requiring them to visit facilities or doctor’s offices.
  4. Patient centricity: Patients are no longer recipients of healthcare, they are active participants. Patient centricity requires more than simply gaining insight from patients; it includes a focus on meeting patient needs and translating patient insights to products that improve outcomes.
  5. Big data analytics and AI modeling: Advances in data analytics and visualization enable researchers to explore and interact with large-scale, often aggregate, bodies of data.
  6. Ever-more data: As the genomics revolution hits the mainstream and real-world data (such as wearable sensors and patient social media trails) becomes accessible and accepted, clinical trials have an explosion of data to ingest, manage and analyze.
  7. Blockchain: Blockchain is a linked data structure that establishes a timestamped, chronological record of history that cannot be tampered with or deleted because no single person or organization has control over the ledger.

 These trends in clinical research indicate a shift from efficiency centric approach to a broad based effectiveness oriented approach.

DNA Drug Design for Cancer Therapy

6A direct genetic approach for cancer treatment is represented through DNA (antisense and other oligonucleotides (ODN’s)) drug design. This approach follows the mechanisms that activate genes known to confer a growth advantage to neoplastic cells. They have the ability to block the expression of these genes which allows exploration of normal growth regulation. As the Progress in DNA drug technology has been rapid, the traditional antisense inhibition of gene expression is now viewed on a genomic scale. Several antisense oligonucleotides are in clinical trials. These antisense oligonucleotides are well tolerated, and are potentially, therapeutically active. These drugs are promising molecular medicines for the treatment of human cancer in the near future.

Antisense or decoy DNA drugs can specifically inhibit gene expression and, as indicated in this review, can ultimately affect abnormal cell proliferation. Downregulation of genes that contribute to cancer progression has been the goal of antisense research, with the expectation that such an approach may lead to a selective or preferential inhibition of tumor growth without harming normal cell growth. Such targets include oncogenes, growth factors, cytokines, protein kinases, phosphoprotein phosphatases, and other positive intracellular regulators of cell growth and cell survival. Although a number of studies have demonstrated in vitro the efficacy of these ODNs against tumor growth, an examination of their long-term effects and pharmacological properties is warranted.

Recent advances in high-throughput screening of gene expression by microarray analysis would permit these studies. Results from these studies will not only provide critical information on ODN pharmacokinetics and toxicity, they will also provide insight into the mechanism of action of these molecules on their own targets and on total cellular gene expression. Such studies will thus narrow the number of selected target genes and the discovery of new target genes for antisense therapeutics.

Revisiting antisense-targeted gene expression on a genome-wide scale will facilitate the discovery of clinically appropriate antisense drugs and provide a unique perspective on the development of new chemotherapeutic combinations based on the molecular actions of these drugs.

Unlike conventional chemotherapy regimens, which depend on the maximum tolerated dose of a given drug to achieve optimal tumor-cell kill, treatment regimens involving antisense ODNs may rely more on the concept of an optimal biological dose. The ultimate goal of therapeutic ODNs is their use as long-term biological gene modulators with minimal or no toxicity. In that case, antisense ODNs represent cytostatic rather than cytotoxic drugs. As such, ODNs can induce tumor cells to differentiate or revert, eventually leading to apoptosis, and reduce or eliminate the chance of relapse in cancer patients following initial treatment. For utmost therapeutic effect, these biological target based antisense DNA drugs can be used at nontoxic minimum doses in combination with low doses of conventional cytotoxic drugs or radiation therapy for cancer.

New Antibody Conjugates in Cancer Therapy

drug_conjugateTargeting of drugs, radiation and protein toxins to cancer selectively with monoclonal antibodies (MAbs) has been considerable as a topic of interest and an area of continued development. Radioimmunotherapy of lymphoma using directly labeled MAbs is of current interest after approval of two radiolabeled anti-CD20 MAbs, as illustrated with the near 100% overall response rate obtained in a recent clinical trial using an investigational radiolabeled 90Y-epratuzumab ,anti-CD22 MAb. The advantage of pre targeted RAIT over directly labeled MAbs is continuing to be validated in preclinical models of solid tumors and lymphoma. Importantly, the advantages of combining RAIT with radiation sensitizers, with immunotherapy, or a drug conjugate targeting a different antigen are being studied clinically and pre clinically. The area of drug-conjugated antibodies is progressing with encouraging data for the trastuzumab-DM1 conjugate in a phase I clinical trial in HER2-positive breast cancer. The technology of Dock-and-Lock platform has contributed to the design and the evaluation of antibody-toxin conjugates and complex antibody-cytokine.


Radioimmunotherapy (RAIT) involves in the application of radiolabeled MAbs for targeted radiotherapy (RT). Both directly radiolabeled MAbs and in vivo radiolabelings of tumor-targeted MAbs by complexation with radiolabeled haptens have been developed.

Radionuclides Used for RAIT

Tumoricidal effects produced by continuous low-dose irradiation from a tumor-targeted radiolabeled MAb. For therapy, α- and β-particle emitters are of practical relevance. There have been numerous investigations with a number of these radionuclides, but for use with whole antibodies, the most promising radionuclides are the β-emitters 131I, 90Y, and 177Lu. 90Y is a max-energy β-emitter (Emax: 2,280 keV; max range: 12 mm) with a 64-h half-life, while 131I has a higher half-life of 8.1 days with low-intermediate energy (610 keV, range: 2.0 mm). 131I is quickly removed from tumor cells after intracellular antibody catabolism so it is not suitable for use with internalizing MAbs. The forms of intracellularly trapped 131I have been designed by us and others for use with internalizing MAbs. A recent study of IMP-R4 template utilized for incorporating residualizing radioiodine for immuno-PET quantitation of de2-7 EGFR expression in glioma in a xenograft model using 124I-IMP-R4–labeled anti-EGFR antibody, ch806. Residualizing use of radioiodine method for clinical RAIT may be supplanted by the availability of the metallic radionuclide 177Lu, which has radiophysical properties similar to those of 131I and radiolabeling chemistry similar to that of 90Y.